Fire1
Venture Round in 2025
Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.
Avation Medical
Series C in 2024
Avation Medical, Inc. is a company focused on developing a non-invasive closed-loop neuromodulation system aimed at treating overactive bladder in a home setting. Incorporated in 2016 and based in Columbus, Ohio, Avation Medical is at the forefront of innovation in wearable nerve stimulation systems. The company emphasizes empowering patients to manage their therapies, facilitating a more personalized approach to care. By leveraging advanced technologies, Avation Medical seeks to transform the neuromodulation market, enhancing the quality of care for individuals with chronic conditions through patient-centric solutions.
EOFlow
Acquisition in 2023
EOFlow Co., Ltd. is a South Korean company specializing in drug delivery solutions, particularly in the development of wearable insulin pumps. Its flagship product, EOPatch, is recognized as the world's smallest full-featured disposable insulin pump, designed to be smarter, better-connected, and longer-lasting than competing devices, all while being more cost-effective. The company plans to enhance EOPatch with a software upgrade that will enable closed-loop insulin control, effectively functioning as an automated insulin delivery system or "artificial pancreas." Additionally, EOFlow is working on an all-in-one wearable disposable artificial pancreas solution, which has received Breakthrough Device designation from the FDA, highlighting its potential impact on diabetes management.
Fire1
Venture Round in 2023
Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.
Klue, Inc. is a digital health technology company founded in 2016 and based in San Mateo, California. It focuses on developing artificial intelligence-based software and wearable technology aimed at promoting healthier eating habits. By leveraging behavioral AI, Klue's solutions help users detect meals and gain insights into their eating behaviors, addressing issues such as obesity. As a subsidiary of Medtronic plc, Klue is positioned to contribute to advancements in digital health and nutrition through its innovative approach to personal wellness.
Nutrino
Acquisition in 2018
Nutrino Health Ltd. is a Tel Aviv-based company that specializes in developing a nutrition insights software platform aimed at providing personalized meal recommendations and health analytics. Founded in 2011, Nutrino utilizes a unique approach known as FoodPrint, which analyzes an individual's biochemistry to offer tailored dietary suggestions that align with their personal health goals and preferences. The platform integrates data from wearables and employs advanced technologies such as image recognition to enhance its nutritional insights. By serving individuals, businesses, and professionals, Nutrino enables users to better understand how food impacts their bodies, facilitating healthier lifestyle choices. As of November 2018, Nutrino operates as a subsidiary of Medtronic plc.
MC10
Venture Round in 2018
MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.
Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.
Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.
Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.
MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.